TRO-01 / TriOar - LARVOL DELTA

Preclinical characterization of TRO-01, a novel CLDN18.2-targeting ADC, with potent anti-tumor efficacy and favorable PK and safety (AACR 2026) - "Toxicology studies in cynomolgus monkeys revealed a favorable safety profile, with a highest non-severely toxic dose (HNSTD) of 40 mg/kg after single dosing. Collectively, these findings highlight TRO-01 as a promising therapeutic candidate for the treatment of CLDN18.2-expressing gastrointestinal cancers."

ADC • Preclinical • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • CLDN18